Abstract library

8 results for "Heaton".
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#377 Survival and Cause of Death in Patients with Small Bowel Neuroendocrine Tumors
Introduction: Small bowel neuroendocrine tumors (SB NETs) have a reported incidence of approximately 0.5-1 per 100 000 population/yr.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#890 Prognostic Validity of the WHO 2010 TNM Staging and Grading Criteria for Pancreatic Neuroendocrine Tumors
Introduction: The TNM staging and grading system developed by the WHO was designed to help prognosticate patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Mr Logan E Mills
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#1209 Pancreatic Neuroendocrine Incidentalomas: When is Surgery in the Patient’s Best Interests?
Introduction: Small PNETs, many of which are diagnosed incidentally, pose a management dilemma. Whilst resection offers curative outcomes, the risks of surgery have led many to adopt surveillance strategies. 2cm is often used as a threshold for malignancy, but reports suggest that this value may not be valid.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Logan Mills
Keywords: PNET
#1239 Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
Introduction: Pancreatic neuroendocrine tumours are graded using the Ki67 antigen in accordance with the WHO 2010 classification. Despite the system’s widespread use, a wide variety of tumour behaviours have been described leading to various proposed revisions.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Logan Mills
Keywords: G3